Institution identification

PURI

https://redirect.ema.europa.eu/resource/3331310

Institution ID

3331310

Institution full name and acronym

Amgen

Institution countries

United States

ENCePP partner

No
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
No

Contact

Studies conducted by the institution

Post-marketing Study Assessing the Serious Cardiovascular Events Among Osteoporotic Patients Initiating Romosozumab in Japan Using the Medical Information Database Network (MID-NET) (20190206)
A cross-sectional study of patients with immune thrombocytopenic purpura and caregivers to estimate the proportion who administer romiplostim correctly after receipt of home administration training materials (20120269)
A cross-sectional survey of patients and caregivers receiving Blincyto in routine clinical practice in Europe to evaluate the effectiveness of additional risk minimisation measures
A Cross-sectional Survey to Evaluate Patient Knowledge of Safety Messages Included in the Patient Safety Brochure and Patient Alert Card for IMLYGIC®
A Cross-sectional Survey to Evaluate Physician Knowledge of Safety Messages Included in the Physician Education Booklet (PEB) for IMLYGIC®
A longitudinal study of 4 cohorts of patients with psoriasis and psoriatic arthritis: one treated with Otezla (apremilast), one with an injectable comparator drug, one with an oral comparator drug and one with an oral and an injectable comparator drug (Otezla-CPRD-001)
A Multi-country Prospective Observational Study to Describe Calcimimetic Use in Haemodialysis Patients
A Multinational Observational Study to Evaluate the Safety of Repatha® in Pregnancy (20150162)
A Non-interventional Pharmacovigilance Study of Osteonecrosis of the Jaw and Infection Leading to Hospitalization Among Patients With Cancer Treated With
XGEVA™ or Zoledronic Acid in Sweden, Denmark, and Norway (20101363)
A post-marketing surveillance study for Repatha Inj. (evolocumab) in Korea text (20160156)
A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC® (Talimogene Laherparepvec) in Clinical Practice to Characterize the Risk of Herpetic Infection Among Patients, Close Contacts, and Health Care Providers (20130193)
A Prospective Cohort Study to Describe Use and Safety of Cinacalcet in Pediatric Patients Receiving Dialysis in the NAPRTCS Registry (20120116)
A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) among Subjects with Non-myeloid Malignancies at High Risk for FN and receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN (20170758)
A Prospective Observational Study to Evaluate Long-term Safety of AMGEVITA in Patients With Rheumatoid Arthritis (20160264)
A Real-world, Prospective, Observational Study of Prolia® (20180401)
A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials
A retrospective analysis of overall response and survival to 1st+ salvage therapy in T-cell and 2nd+ salvage therapy in B-cell pediatric acute lymphoblastic leukemia (20180065) (Retrospective pediatric ALL retrospective response)
A retrospective analysis of pre-existing and acquired major adverse cardiovascular events (MACE) in a real world cohort of multiple myeloma (MM) patients treated with proteasome inhibitors
A Survey of Experiences and Opinions Regarding Skin Toxicities Associated with Vectibix Among mCRC Patients
A Survey of Medical Oncologist’s Opinions and Perceptions Regarding the Management of Dermatologic Toxicities among mCRC Patients Treated with Vectibix (20160258)
A two-stage, prospective observational study describing the use and effectiveness of XGEVA®/ANJIAWEI® for the prevention of skeletal related events in patients with bone metastases from solid tumors relative to ZOMETA® in the People's Republic of China (20190036)
All Case Post Marketing Drug Use Result Survey for Blinatumomab in Japan (20170655) (Blinatumomab All Case PMS Japan)
An Observational Case Series to Describe Women Exposed to Repatha During Pregnancy and Infant Outcomes During the First Year of Life (20200408)
An Observational Registry Study To Evaluate The Use And Safety Of Cinacalcet Among Paediatric Patients With Secondary Hyperparathyroidism (20180204)
An observational study describing the effectiveness and safety of BLINCYTO® in Chinese adults with Philadelphia chromosome-positive relapsed or refractory B-cell precursor Acute Lymphoblastic Leukemia (Ph+ R/R B-cell precursor ALL) (20210061)
An observational study of blinatumomab safety and effectiveness, utilisation, and treatment practices (20150136)
An observational study of patients with Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia in the US (20150253)
An Observational Study to Assess the Effectiveness of the Neulasta® Patient Alert Card and to Measure Medication Errors Related to the Use of the Neulasta® On-Body Injector (20170701)
An Observational Study to Describe Women Exposed to Apremilast During Pregnancy and Infant Outcomes During the First Year of Life (20210218)
An Observational Study to Estimate Incidence Rates of Heart Failure Among US Racial and Ethnic Minority Patients With Multiple Myeloma Treated or Not Treated With Carfilzomib
An Observational Study to Evaluate the Potential Association Between Cinacalcet and Gastrointestinal Bleeding (20170171)
An Observational Study to Evaluate the Potential Association Between ParsabivTM and Gastrointestinal Bleeding (20170561)
APPRECIATE™ (APREmilast ClinIcAl Treatment Experience in psoriasis): A Multi-center, Retrospective Observational Study of Real-World Experience of Psoriasis Patients Treated with Apremilast in Clinical Dermatology Practice.(20200066 / CC-10004-PSOR-013)
Assessment of the ‘Managing Advanced Cancer Pain Together’ (MACPT) tool to facilitate communication on total cancer pain between advanced cancer patients and their healthcare professionals (20160376)
Association Between Granulocyte Colony Stimulating Factor (G-CSF) use and Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Among Elderly Patients With Breast (Stage I-III), lung (Stage I-III) or Prostate (Stage I-IV) Cancer
Burden of Illness Among Patients with Gout and Treated with Pegloticase (20240302)
Burden of serious infection in patients with rheumatoid arthritis treated with Prolia ovserved in a clinical setting (20140127)
Calcimimetics Adherence and Preference Study in the Management of Secondary Hyperparathyroidism in Europe
Canadian Retrospective Observational Study of MVASI in metastatic Colorectal Cancer (20180360)
Characteristics and Risk Profile of Adult Patients Treated with Apremilast Included in the British Association of Dermatologists Biologic Interventions Register (BADBIR) : A Retrospective Database Analysis (20210230)
Characterizing Otezla Use and Exposure Among Pregnant Women (20220012)
Characterizing Repatha use among adult pregnant women, adult women of childbearing age and within the adult general population (NA)
Characterizing the management of hypocalcemia among European hemodialysis patients receiving cinacalcet (20150330)
Characterizing the Management of Hypocalcemia Among Patients on Hemodialysis Receiving Cinacalcet Treated Within a Large US Dialysis Provider (20140132)
Cinacalcet Use and the Risk of Gastrointestinal (GI) Bleeding Among Hemodialysis Patients with Secondary Hyperparathyroidism (SHPT) in DOPPS
Clinical Characteristics of The First IMLYGIC™ Patients With Unresectable Stage IIIB-IVM1a Melanoma Treated in Routine Clinical Practice, in Selected European Countries (20140413)
Clinical Characteristics, Including History of MI and Stroke, Among US Post-menopausal Women Initiating Treatment With Romosozumab and Other Anti-osteoporosis Therapies (20190205)
Clinical Systematic Literature Review (SLR) of Ph(-) B-ALL in High-risk First Relapse Paediatric Patients
Comparative Effectiveness of Osteoporosis Medications Among Female Medicare Fee-For-Service (FFS) Beneficiaries in the United States (20210028)
Comparative effectiveness of sotorasib versus docetaxel in second line and beyond (2L+) among patients with advanced non-small cell lung cancer (NSCLC) in the Flatiron Health (FH) Enhanced Datamart (EDM)
Comparative Effectiveness of Sotorasib Versus Docetaxel Monotherapy in Second Line and Beyond (2L+) Among Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in the Cancer Analysis System Database in England (20240164)
Comprehensive Analysis of Clinical Parameters That May Inform the Choice of Dose Regimen for Carfilzomib 20/27mg/m2 or 20/56mg/m2 With and Without Dexamethasone (20200381)
CROSSROADS-1: Treatment Outcomes among Tezspire Users: A Claims Data Study (20230159)
CROSSROADS-2: Clinical Characteristics, Treatment Patterns, and Treatment Outcomes Among Users of Tezspire: An Electronic Medical Record (EMR) study (20220066)
Denosumab Global Safety Assessment in Multiple Observational Databases (20090522)
Effect of Cinacalcet Discontinuation on Biochemical Control for Medicare Beneficiaries with Part D Coverage Treated within a Large US Dialysis Provider (20130335)
Effectiveness of the Nplate Additional Risk Minimisation Materials Implemented in Australia (20210176)
Effectiveness, Efficacy, and Safety of XGEVA (denosumab) in Chinese Patients With Giant Cell Tumor of Bone (GCTB): A Systematic Literature Review (20220044)
Estimating Event Rates Using the Medication Cohort Module: Hypertension and Negative Control Outcomes in New Users of Onabotulinumtoxin A and Monoclonal Antibodies Targeting the Calcitonin-Gene-Related Pathway in the Marketscan EarlyView Claims Database (20200218)
Estimation of Off-Label Use of XGEVA® (denosumab) Using Population-Based Databases in Denmark (20101335)
EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care DA VINCI
Evaluation of Long-term Safety in Paediatric Patients With B-precursor Acute Lymphoblastic Leukemia (ALL) who Have Been Treated With Either Blinatumomab or Chemotherapy, Followed by Transplantation (20180130) (Paediatric long-term follow up study)
EVENITY® Risk Minimisation Materials Effectiveness Measurement in Australia (20220120)
Evolocumab Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance Study (20150338)
Expanded access of Blincyto® in patients with acute lymphoblastic leukaemia: a retrospective observational study (Neuf Study) (20160441)
GARDENIA: A Multi-country Observational Serial Chart Review Study of KANJINTI use in Europe
GENESIS: AIMOVIG® Pregnancy Exposure Registry (20180125)
Getting to an imprOved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia management (GOULD): a Registry of High Cardiovascular Risk Subjects in the United States
Global burden of hip fractures – trends in incidence, post-fracture treatment, and mortality; a multicountry, observational study (20190532)
Granulocyte Colony-Stimulating Factor (“G-CSF”): Patient profiles, Scheduling Patterns and Clinical Outcomes
Healthcare Providers’ Awareness of the risks and safe use conditions associated with BLINCYTO®: A REMS Assessment Survey (20170108)
Healthcare Providers’ Awareness of the Risks and Safety Associated With BLINCYTO® use: A 2021 REMS Assessment Survey (20210065)
Hearing loss and risk of major osteoporotic fracture: a population-based cohort study in the United Kingdom (20200418)
Incidence of Cardiovascular and Cerebrovascular Events Among Postmenopausal Women and Men With Osteoporosis Who Initiated Treatment With Denosumab or Zoledronic Acid - A Retrospective Cohort Study (20190038)
Incidence of Hematologic and Non-Hematologic Malignancies, Thrombotic Events, and Autoimmune Disorders in Unrelated Normal Donors Undergoing Bone Marrow Harvest Versus Peripheral Blood Stem Cell Mobilization with Recombinant Human Granulocyte Colony-Stimulating Factor (20130209)
Incidence of new Primary Malignancies Among Patients With Bone Metastases From Breast, Prostate, or Lung Cancer Treated With XGEVA or Intravenous Zoledronic Acid: a Retrospective Cohort Study (20170728)
Inpatient Constipation Among Migraine Patients Treated With Preventive Medications: A Retrospective Cohort Study in a United States Electronic Health Record Database
Integrated Retrospective Analysis of Metastatic-related and Non metastatic-related Fractures in Studies 20050136, 20050244, and 20050103
Long Term Post Marketing Drug Use Result Survey for Blinatumomab in Japan (20180238) (Blinatumomab Long Term PMS Japan)
Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan (20140409) (Evolocumab Long term PMS Japan)
Long-term Follow-up of Adult Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia Relapsed Refractory Patients Enrolled in Study 00103311 (TOWER Follow-up Study)
Longitudinal study on the epidemiology and management of auto-immune thrombocytopenia (AITP) in Algeria
Medical Records Review to Describe the Patterns of KRAS Testing and Vectibix Use in Europe (20101120)
Multicenter Assessment of Treatment Outcomes in a Historical Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia (20180232) (Retrospective relapse/refractory AML outcomes)
Nordic Country Patient Registry for Romiplostim (NCPRR): Population-Based Prospective Annual Assessment of Safety of Romiplostim Treatment in Adult Patients with Chronic Idiopathic (Immune) Thrombocytopenic Purpura (ITP) Based on National Health Registry Systems in Denmark, Sweden and Norway (20070797)
Observational Serial Chart Review of Repatha® Use in European Subjects with Hyperlipidaemia (20130296)
Observational Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Erenumab-aooe During Pregnancy (20180172)
Osteonecrosis of the Jaw (ONJ) Case Registry
OTEZLA® Tablets Drug Use-Results Survey (CC-10004-PSOR-018)
OTEZLA® tablets General use-results survey (BCT) (20200279)
Overall survival and incidence of adverse events in B-cell acute lymphoblastic leukemia (ALL) patients after allogeneic stem cell transplant: blinatumomab vs non-blinatumomab chemotherapy-- an analysis of the Center for International Blood and Marrow Transplant Research database (20170610) (Transplant outcomes among ALL in CIBMTR)
Periodic Knowledge, Attitudes, and Behavior (KAB) Survey of Certified Prescribers to Assess Understanding of the Risks with the Prolia Risk Evaluation and Mitigation of Strategy (REMS) (20240121)
Periodic Knowledge, Attitudes, and Behavior (KAB) Survey of Patients and/or Caregivers to Assess Understanding of the Risks with the BKEMV™ Risk Evaluation and Mitigation Strategy (REMS) (20240214)
Persistence and compliance to anti-osteoporosis medications in the United Kingdom using the Clinical Practice Research Datalink (CPRD) (20160192)
Persistence of AMGEVITA® in patients with plaque psoriasis: a retrospective database analysis from the British Association of Dermatology Biologics and Immunomodulators Register (20210149)
Post-marketing Surveillance Study for Sotorasib in South Korea (20200009)
Postmarketing Surveillance Study for Kyprolis® (carfilzomib) in Korea (20160117)
Postmarketing Surveillance Study of EVENITY (Romosozumab) in South Korea (20170753)
Postmarketing Surveillance Study of Prolia (Denosumab) in South Korea
Postmarketing Surveillance Study of XGEVA (Denosumab) in South Korea (20160198)
POWER: Real World Data of 1st line panitumumab treatment in combination with chemotherapy in non resectable wild type (WT) RAS metastatic colorectal cancer (mCRC) subjects in Austria, Bulgaria, Croatia, Czech Republic, Hungary, Poland, Slovenia, Romania, Russia, Greece an Observational Ambidirectional Study (20170734)
Primary Immune Thrombocytopenia Treated with Romiplostim (20140451)
Prolia® persistence in post-menopausal women with osteoporosis, over 70 years, at increased risk of fracture, treated in routine clinical practice in Bulgaria
Prolia® Postmarketing Active Safety Surveillance Program for Soliciting Adverse Events of Special Interest in the United States (PASP-EMR Program)
Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving Q2W chemotherapy regimen: A systematic review of efficacy, effectiveness, and safety (20190355) (Pegfilgrastim in Q2W regimen: A systematic review)
ProSpective MultIcenter ObservationaL Study on the Quality of Life of mCRC RAS Wild-type Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line of Treatment (20140383)
Prospective Observational Cohort Study to Describe the Use of Vectibix® in Combination With Chemotherapy in Routine Clinical Practice for Patients With Wild-type KRAS Metastatic Colorectal Cancer (20120100)
Prospective Observational Non-interventional Study to Describe Characteristics and Management of Patients With Giant Cell Tumor of Bone Treated With XGEVA and Its Use in Routine Clinical Practice in France (20150360)
Prospective Observational Study to Describe Characteristics and Management of Patients With Osteoporosis Treated With Prolia® in Routine Clinical Practice in Poland (20160178)
Prospective Observational Study to Describe Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France and its use in Routine Clinical Practice (20130240)
Prospective observational study to describe routine use of XGEVAâ for prevention of skeletal related events (SREs) in subjects with bone metastases from prostate carcinoma in Bulgaria (20180095)
RAStik: A Retrospective Cohort Analysis of Survival and Treatment Outcomes of Docetaxel in KRAS G12C Mutated Locally Advanced or Metastatic NSCLC (20190411)
Real-world Comparative Effectiveness of Anti-EGFRs with Doublet Chemotherapy Versus Doublet Chemotherapy with or without Bevacizumab in Firstline Among RAS/RAF Wild-type, non-dMMR/MSI High mCRC Patients with Left-sided Primary Tumors in the Flatiron Health CRC Enhanced Datamart (20240215)
Real-world Evidence of the Use of a Carfilzomib Triplet Including an Anti-CD38 Antibody in Patients With Multiple Myeloma who Have Received at Least one Prior Therapy (20200445)
Real-world Evidence of the Use of Carfilzomib Among Multiple Myeloma Patients in Europe Who Have Received at Least One Prior Therapy (Use of Carfilzomib In Multiple Myeloma Patients)
Retrospective Analysis of Second Primary Malignancies (SPM) Data From ASPIRE and ENDEAVOR Studies (20220146)
Retrospective Cohort Study Evaluating Clinical Outcomes in Patients with Granulomatosis with Polyangiitis (GPA)/Microscopic Polyangiitis (MPA) Treated with Avacopan (20230026)
Retrospective Multicenter Study Describing Baseline Clinical Characteristics and Outcomes in BLINCYTO® Treated Adult Patients With Relapsed or Refractory B-cell Precursor ALL Stratified by Baseline Disease Burden and Cytoreductive Therapy (20200012)
RETrospective Observational Study of Evolocumab Use in Spanish Endocrinology Units (RETOSS-Endo) (20160140)
Risk factors and incidence of inpatient constipation and inpatient constipation with serious complications among migraine patients treated with erenumab: A retrospective cohort study in a US Electronic Health Record Database (20200087)
Risk factors For Bone Pain among Neulasta® Users (20120320)
Risk factors for cardiac events in carfilzomib-treated patients in the Marketscan database (20160186)
Risk of Hypertension, Acute Myocardial Infarction, and Stroke in Migraine Patients Treated With Migraine Preventive Medications (20200403)
Risk Prediction, Prognosis and Management of Cardiac Events among Patients with Multiple Myeloma (20160220)
Romiplostim effectiveness stratified on duration of immune thrombocytopenia at initiation
Special Drug Use-Results Surveillance (all-case) for sotorasib in patients with KRAS G12C-mutated, unresectable, advanced and/or recurrent non-small-cell lung cancer, that has progressed after systemic anticancer therapy in Japan (20210051)
Specific Drug Use-results Surveillance (Long-term) for Erenumab in Migraine Patients in Japan (20210048)
Survey of Oncology Practitioners Prescribing XGEVA® in Europe to Evaluate Their Knowledge of XGEVA® Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw (20110102)
Survey of Physicians, Pharmacists, and Nurses Involved in the Prescribing, Preparation and Administration of Blincyto in Europe to Evaluate the Effectiveness of Additional Risk Minimization Measures (20150163)
Targeted Literature Review to Describe Safety Outcomes in Immune Thrombocytopenia Patients Treated With Thrombopoietin-Receptor Agonists
Tarlatamab vs. Real-world Physicians’ Choice Therapies in Patients with Relapsed or Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment: Patient-level Indirect Treatment Comparison (ITC) of DeLLphi-301 vs. Flatiron Real-world Data
The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (20180059) (cvMOBIUS)
The Incidence and Risk factors for Hypocalcaemia Among Osteoporosis Patients Receiving Romosozumab or Other Antiresorptive Therapy in Japan -- A Retrospective Cohort Study Within the Medical Information Database Network (MID-NET)
The Safety and Clinical Effectiveness of Denosumab Among Chinese Men With Osteoporosis – a Real World Study in Taiwan (20210040)
The Safety and Effectiveness of Denosumab Among Chinese With Osteoporosis and Glucocorticoid Exposure – a Real World Study in Taiwan (20220054)
The use and safety of XGEVA or Zoledronic acid in clinical practice among Chinese patients with bone metastases from breast, lung, or prostate cancer – a retrospective cohort study within Taiwan’s Health Insurance Research Database (20190412)
The use, safety, and effectiveness of Prolia in clinical practice among Chinese women with post-menopausal osteoporosis ─ Taiwan and Hong Kong (20180325)
Topological Analysis of the baseline characteristics of relapsed and/or refractory multiple myeloma (R/R MM) patients treated with carfilzomib in clinical trials to identify cohorts that represent levels of risk of select cardiovascular adverse events (CV AEs) in that patient population (20190506)
Use of Bone Marrow Biopsies in Patients With Chronic Immune Thrombocytopenia: Predictors For, And Prognosis After – a Nordic Population-based Cohort Study And a Nested Case Control Study
Use of Erythropoiesis Stimulating Agents (ESA) in Patients With Non-myeloid Malignancies Receiving Myelosuppressive Chemotherapy 2014 – 2021 (20170210)
Use of Erythropoiesis Stimulating Agents (ESAs) in Patients Receiving Myelosuppressive Chemotherapy in Europe and the UK (20190404)
Users of pegfilgrastim less than or equal to 13 years of age (20180440) (Users of pegfilgrastim =< 13 years)
Users of pegfilgrastim less than or equal to 13 years of age (20200114)
Utilization of Romiplostim in Myelodysplastic Syndromes (MDS) within the Medicare Population: A Study Based on Data from the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database – Original Analysis & Follow-up Analysis (20190354, 20150177)